Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

Guideline | Management of castration-resistant prostate cancer.

17 Nov, 2022 | 12:28h | UTC

2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) – Canadian Urological Association Journal

 

Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.

15 Nov, 2022 | 12:58h | UTC

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial – The Lancet

Commentary: Non-hormonal therapy reduces hot flashes and night sweats in women who have been diagnosed with breast cancer – Monash University 

 

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

15 Nov, 2022 | 12:52h | UTC

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up – Annals of Oncology

 

Commentary from the author on Twitter

https://twitter.com/ArndtVogel/status/1590634413377081344

 

RCT | Comparison of acupuncture vs. sham acupuncture in the treatment of aromatase inhibitor–related joint pain.

15 Nov, 2022 | 12:47h | UTC

Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain: A Randomized Clinical Trial – JAMA Network Open

Commentary: Aromatase inhibitors and acupuncture in breast cancer: Spinning a negative study, four years later – Science-based Medicine

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1591113526222913538

 

RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

11 Nov, 2022 | 13:55h | UTC

[News release – not published yet] Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – American Society for Radiation Oncology (ASTRO) Annual Meeting

 

Phase 2 RCT | Efficacy of Bemarituzumab in patients with FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma.

11 Nov, 2022 | 13:02h | UTC

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Single-arm phase 1b study | Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma.

11 Nov, 2022 | 13:00h | UTC

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial – The Lancet Oncology (link to abstract – $ for full-text)

 

NICE Guideline Update | Colonoscopic surveillance in adults with inflammatory bowel disease or adenomas.

10 Nov, 2022 | 14:16h | UTC

Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn’s disease or adenomas – National Institute for Health and Care Excellence

Related:

British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines – Gut

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

Evidence-based clinical practice guidelines for management of colorectal polyps – Journal of Gastroenterology

Meta-analysis: Risk of colorectal cancer and cancer related mortality after detection of low-risk or high-risk adenomas, compared with no adenoma, at index colonoscopy

Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer – Gastroenterology

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – Endoscopy

 

Single-arm P2 study | Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas.

9 Nov, 2022 | 12:24h | UTC

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma – The University of Texas MD Anderson Cancer Center

 

Phase 2 RCT | Concurrent Bevacizumab and reirradiation vs. Bevacizumab alone as treatment for recurrent glioblastoma.

9 Nov, 2022 | 12:21h | UTC

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme – OncLive

 

Review | Direct oral anticoagulants for the prevention and acute treatment of cancer-associated thrombosis.

9 Nov, 2022 | 12:13h | UTC

Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis – Vascular Health and Risk Management

 

RCT | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma.

9 Nov, 2022 | 12:12h | UTC

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.

8 Nov, 2022 | 12:11h | UTC

Neoadjuvant relatlimab and nivolumab in resectable melanoma – Nature

News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release

 

Commentary on Twitter

 

SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.

8 Nov, 2022 | 12:00h | UTC

Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials – Frontiers in Oncology

 

RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.

7 Nov, 2022 | 12:26h | UTC

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter

 

Post-trial follow-up | Long-term outcomes with stereotactic radiosurgery vs. whole-brain RT for resected brain metastasis.

7 Nov, 2022 | 12:22h | UTC

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Survivors face less late cognitive deterioration after stereotactic radiosurgery than WBRT – medwire News

Original Study: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Cohort Study | Fracture risk among older cancer survivors compared with older adults without a history of cancer.

4 Nov, 2022 | 13:33h | UTC

Fracture Risk Among Older Cancer Survivors Compared With Older Adults Without a History of Cancer – JAMA Oncology (free for a limited period)

Commentary: Frailty-Related Fracture Risk Higher for Seniors With Cancer History – HealthDay

 

M-A | Efficacy of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer.

4 Nov, 2022 | 13:22h | UTC

Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis – JAMA Network Open 

 

Cohort Study | Association of Taxane type with chemotherapy-induced peripheral neuropathy in patients with breast cancer.

4 Nov, 2022 | 13:15h | UTC

Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer – JAMA Network Open 

 

M-A | Risk of major adverse events associated with gabapentinoid and opioid combination therapy.

4 Nov, 2022 | 13:13h | UTC

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis – Frontiers in Pharmacology

 

ASCO Policy Statement | Electronic nicotine delivery systems.

3 Nov, 2022 | 14:03h | UTC

Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology – Journal of Clinical Oncology

Commentary: Updated policy regarding electronic nicotine delivery systems – Yale Cancer Center

 

Cohort Study | Mental health morbidities and time to cancer diagnosis among adults with colon cancer in England.

3 Nov, 2022 | 13:55h | UTC

Mental Health Morbidities and Time to Cancer Diagnosis Among Adults With Colon Cancer in England – JAMA Network Open 

Invited Commentary: The Interface Between Colon Cancer and Mental Health Morbidities – JAMA Network Open

 

Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.

3 Nov, 2022 | 13:39h | UTC

Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

Commentaries:

Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLC – Cancer Network

Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News

 

Commentary on Twitter

 

Opinion | Should disease-free survival be used as a regulatory or clinical end point for adjuvant therapy of cancer?

3 Nov, 2022 | 13:37h | UTC

You’re Cured Till You’re Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer? – Journal of Clinical Oncology

 

NICE Guideline Update | Lung cancer: diagnosis and management.

2 Nov, 2022 | 14:28h | UTC

Lung cancer: diagnosis and management – National Institute for Health and Care Excellence

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.